MEET OUR LEADERSHIP TEAM

Nanomab is led by a highly experienced executive team with decades of experience across the pharmaceutical and life science sectors. 

Paul Edwards MBE
Paul Edwards MBEChief Executive Officer
Paul has 40 years’ experience in the pharmaceutical and life science arena. A graduate chemist, he initially worked for Beecham Pharmaceuticals and Genzyme Corporation, where he headed the UK operations for the company. In 2000, he joined the UK based biosimilars’ organisation, GeneMedix plc as Chief Executive Officer, and successfully led a major funding round taking the company to a dual listing on the London and Singapore Stock Exchanges. More recently, Paul has acted as a NED to Goldshield Group plc and BioProducts Laboratories and oversaw the sale of both organisations to Private Equity Groups, as well as serving as Managing Partner and board member of the global Executive Search Group, Horton International.
Paul is a familiar face in the UK biotech arena, having been the Chairman of the UK BioIndustry Association’s Manufacturing Advisory Committee and was the recipient of the Donald Medal for services to Biochemical Engineering (1999). In 1997 he received an MBE for services to biotechnology
Dr. HH Ting
Dr. HH TingCo-founder and Chief Scientific Officer
Dr. Ting is a scientist, entrepreneur and angel investor. He has extensive experience in nuclear medicine and the Chinese healthcare sector. Most recently, he served as CEO and co-founder of Oxford Vacmedix and Biovue Technology Ltd. He was also the co-founder of Genemedix Plc., a biotechnology company once co-listed in main boards of LSE and SSE before its acquisition by the Reliance Group. Earlier in his career, he was the China General Manager of Amersham International Plc. and worked as a consultant for Westinghouse Electric, J&J and GE Healthcare. Dr. Ting received his DPhil degree from the University of Oxford, and held a permanent university senior research staff position under Professor J.E.Baldwin’s group before he left for industry.
Robin Pakenham
Robin PakenhamChief Financial Officer
After graduating in Engineering Mathematics, Robin trained with KPMG as a Chartered Accountant, leaving in 1992. He then spent 9 years at Legal & General Ventures, one the largest European LBO/PE Investors of the 1990s. In the last 10 years, Robin has been a high impact interim and start-up CFO delivering value in Corporate Finance-rich situations, including: PYReco raised £100m, the sale of BioProducts Laboratory to Bain Capital for £230m, and CP Electronics was sold to Legrand for £75m. In 2019, he was CFO of Kind Consumer, as it raised £14m of equity in two rounds prior to the launch of the medically licenced nicotine inhaler, Voke.
WH Huang
WH Huang China General Manager
Mr. Huang has over 20 years of experience in research, development and commercialization in the Chinese biotechnology sector. Prior to joining NanoMab, he was an associate professor at The Institute of Translational Medicine of Shanghai General Hospital. He also served as the SVP of Cell Signaling Company and R&D director of Shanghai State Biotechnology Co., Ltd. Mr. Huang holds a master’s degree in bioengineering from Fudan University and an MBA from Richmond Business Administration College.
Nicholas CL Wong
Nicholas CL Wong Project Director
Nicholas has broad experience in the development of innovative cancer treatments. Prior to joining NanoMab, he held the position of project manager in Jiangsu Laitai Medical Biotech Ltd, responsible for the early development of a liver cancer specific peptide pharmaceutical. He also served as application scientist at Roche Diagnostic where he was in charge of implementing cancer molecular diagnostics in Hong Kong. Nicholas is a founder of Novus Life Sciences Ltd, a Hong Kong Science and Technology Park biotechnology incubator company focusing on the development of novel bone cement formulations. Nicholas received his academic training and PhD in cancer biology from the University of Hong Kong.
Dr. Gitasha Chand
Dr. Gitasha Chand Clinical Research Director
Gitasha has extensive experience in the clinical development of radiopharmaceuticals. Immediately prior to joining NanoMab, she was a clinical research associate at Jiangsu Laitai Medical Biotech Ltd, in charge of the China-wide clinical development of Re-188 HEDP, a radiopharmaceutical for the palliative treatment of patients with metastatic bone disease. Earlier in her career, she was a resident trainee at Shanghai East Hospital and Shanghai Bao Shan CDC where she performed extensive research on infectious diseases. Gitasha holds an MBBS from Tongji University Medical School, Shanghai and she is specialized in emergency and disaster medicine.
 Dr. Levente Meszaros
Dr. Levente MeszarosSenior Project Manager
Levente has over 10 years of experience in the development of radiopharmaceuticals. Earlier in his career he worked as a research associate and radiation protection supervisor at King’s College London, where his research focused on the development of radiopharmaceuticals targeting osteolytic bone disease and novel tracers for ex vivo cell radiolabeling. Upon leaving King’s College London he worked at BioProbe Ltd as project leader and at Theragnostics Ltd as quality control scientist. Levente holds master’s degrees in chemistry, clinical chemistry and radiopharmaceutics from the University of Szeged, Hungary and King’s College London and a PhD in imaging sciences and radiation biology from King’s College London.